Progressive symmetric erythrokeratodermia
| Progressive symmetric erythrokeratodermia | |
|---|---|
| Synonyms | Erythrokeratodermia variabilis et progressiva |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Red patches, thickened skin |
| Complications | Skin infection, psychosocial impact |
| Onset | Childhood |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | Family history |
| Diagnosis | Clinical examination, genetic testing |
| Differential diagnosis | Psoriasis, Ichthyosis |
| Prevention | N/A |
| Treatment | Emollients, Keratolytics, Retinoids |
| Medication | Acitretin, Isotretinoin |
| Prognosis | N/A |
| Frequency | Rare |
| Deaths | N/A |
Progressive symmetric erythrokeratodermia (PSEK) is a rare genetic disorder that affects the skin. It is characterized by well-defined, symmetric, erythematous, and hyperkeratotic plaques. The condition is typically present at birth or appears in early childhood.
Symptoms[edit]
The primary symptom of PSEK is the presence of red, scaly patches on the skin. These patches are usually symmetric and can be found on the limbs, buttocks, and sometimes the face. The severity of the symptoms can vary greatly from person to person. Some individuals may experience mild symptoms, while others may have severe skin abnormalities.
Causes[edit]
PSEK is caused by mutations in the loricrin gene. This gene provides instructions for making a protein that is a major component of the cornified cell envelope, a structure that provides strength and resilience to the skin. Mutations in the loricrin gene disrupt the normal formation of the cornified cell envelope, leading to the skin abnormalities seen in PSEK.
Diagnosis[edit]
Diagnosis of PSEK is based on the clinical presentation of the skin abnormalities. A skin biopsy may be performed to confirm the diagnosis. Genetic testing can also be used to identify mutations in the loricrin gene.
Treatment[edit]
There is currently no cure for PSEK. Treatment is aimed at managing the symptoms and may include the use of emollients, keratolytics, and retinoids. In some cases, systemic retinoids may be used to reduce the thickness of the skin.
Prognosis[edit]
The prognosis for individuals with PSEK is generally good. The condition does not affect life expectancy, but it can cause significant discomfort and cosmetic concerns.
See also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


